Sjogren's SSA Ro52/Ro60 Antibodies
Order Name
Sjogren SSA
Test Number: 5599902
Revision Date 01/06/2020
Test Number: 5599902
Revision Date 01/06/2020
| Test Name | Methodology | LOINC Code |
|---|---|---|
|
Sjogren's SSA Ro52
|
Chemiluminescence Assay | 56549-9 |
|
Sjogren's SSA Ro52 Interpretation
|
Interpretive information. | |
|
Sjogren's SSA Ro60
|
Chemiluminescence Assay | 63411-3 |
|
Sjogren's SSA Ro60 Interpretation
|
Interpretive information. |
| SPECIMEN REQUIREMENTS | ||||
|---|---|---|---|---|
| Specimen | Specimen Volume (min) | Specimen Type | Specimen Container | Transport Environment |
| Preferred | 2 mL (1 mL) | Serum | Clot Activator SST | Frozen |
| Instructions | Allow specimen to clot completely at room temperature. Separate serum from cells ASAP or within 2 hours of collection. Stability: Room Temperature 8hrs, Refrigerated: 48hrs, Frozen: 30 days. |
|||
| GENERAL INFORMATION | |
|---|---|
| Testing Schedule | Mon-Fri |
| Expected TAT | 1-3 Days |
| Clinical Use | SSA/Ro52 and Ro60 antibodies
Anti-SSA/Ro antibodies may be present in patients with a range of autoimmune disorders, including systemic lupus erythematosus (32%), Sjögren's syndrome (59%), idiopathic inflammatory myopathies (19%), systemic sclerosis (21%), mixed connective tissue disease (29%), rheumatoid arthritis (15%), primary biliary cholangitis/primary biliary cirrhosis and undefined connective tissue disease. The prevalence of anti-Ro60 and anti-Ro52 antibodies in patients with SLE was reported to be 49% and 43%, respectively. In patients with Sjögren's syndrome, these antibodies were detected in 67% and 75% of affected individuals. The presence of anti-Ro52 antibodies may be associated with more severe disease. The prevalence of the two types (Ro52 & Ro60) of anti-Ro antibodies diverge in patients with other autoimmune diseases. Anti-Ro52 antibodies but not anti-Ro60 antibodies were detected in patients with idiopathic inflammatory myopathies (35% versus 0%), and anti-Ro52 was more common than anti-Ro60 in patients with systemic sclerosis (19% versus 6%) and Mixed Connective Tissue Disease (29% versus 19%). Women with anti-Ro antibodies, with or without anti-La antibodies and with or without autoimmune disease, are at increased risk for having a child with neonatal lupus syndrome. |
| CPT Code(s) | 86235x2 |
| Lab Section | Immunology - Serology |